Sanofi subsidiary Genzyme agrees to pay $22.3 million to settle accusations that its sales rep encouraged off-label use of the Seprafilm surgical product. Massachusetts-based Genzyme Corp., a subsidiary of Sanofi (NYSE:SNY), agreed to pay $22.3 million to settle a whistleblower lawsuit accusing the company of off-label marketing of its Seprafilm surgical product. Seprafilm protects organs and muscles following surgery, forming a barrier that prevents them from attaching to one another during healing.
Help employers find you! Check out all the jobs and post your resume.
